{"id":89194,"date":"2023-11-27T08:03:49","date_gmt":"2023-11-27T13:03:49","guid":{"rendered":"https:\/\/ifintechworld.com\/uncategorized\/sanofi-and-regeneron-set-to-file-for-fda-approval-of-dupixent-for-copd\/"},"modified":"2023-11-27T08:03:51","modified_gmt":"2023-11-27T13:03:51","slug":"sanofi-and-regeneron-set-to-file-for-fda-approval-of-dupixent-for-copd","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=89194","title":{"rendered":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD"},"content":{"rendered":"<div>\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<p><span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p><span itemscope=\"\" itemtype=\"http:\/\/schema.org\/Corporation\"><span itemprop=\"name\"> Sanofi <\/span><\/span> (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration (FDA) for their drug Dupixent (dupilumab) before the end of December, following promising trial results. Dupixent, already known for treating conditions such as asthma and atopic dermatitis, has now shown efficacy in a second Phase 3 trial, NOTUS, for treating chronic obstructive pulmonary disease (COPD).<\/p>\n<p>The NOTUS trial met its primary endpoint, demonstrating a significant 34% reduction in COPD exacerbations. This success mirrors the results from the earlier Phase III BOREAS trial. The European Medicines Agency (EMA) is currently reviewing similar data. If approved, Dupixent would become the first biologic treatment available for patients with COPD, representing a substantial new market opportunity.<\/p>\n<p>George Yancopoulos, the Chief Scientific Officer of Regeneron, expressed readiness for an urgent FDA submission, highlighting the potential impact of Dupixent in treating COPD. The New England Journal of Medicine has documented the significance of this development, indicating the potential for Dupixent to enter a massive new therapeutic area.<\/p>\n<p><em>This article was generated with the support of AI and reviewed by an editor. For more information see our T&amp;C.<\/em><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.investing.com\/news\/stock-market-news\/sanofi-and-regeneron-set-to-file-for-fda-approval-of-dupixent-for-copd-93CH-3243605\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration (FDA) for their drug Dupixent (dupilumab) before the end of December, following promising trial results. Dupixent, already known for treating conditions such as asthma and atopic dermatitis, has now shown efficacy in a second [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":89195,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[1],"tags":[83],"class_list":["post-89194","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-uncategorized","tag-featured","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld<\/title>\n<meta name=\"description\" content=\"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=89194\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=89194\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-27T13:03:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-27T13:03:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/LYNXNPEB9S09V_L.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"728\" \/>\n\t<meta property=\"og:image:height\" content=\"485\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=89194#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=89194\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD\",\"datePublished\":\"2023-11-27T13:03:49+00:00\",\"dateModified\":\"2023-11-27T13:03:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=89194\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=89194#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=89194\",\"url\":\"https:\/\/ifintechworld.com\/?p=89194\",\"name\":\"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-11-27T13:03:49+00:00\",\"dateModified\":\"2023-11-27T13:03:51+00:00\",\"description\":\"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=89194#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=89194\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=89194#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld","description":"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=89194","og_locale":"en_US","og_type":"article","og_title":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld","og_description":"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration","og_url":"https:\/\/ifintechworld.com\/?p=89194","og_site_name":"iFintechWorld","article_published_time":"2023-11-27T13:03:49+00:00","article_modified_time":"2023-11-27T13:03:51+00:00","og_image":[{"width":728,"height":485,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/LYNXNPEB9S09V_L.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=89194#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=89194"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD","datePublished":"2023-11-27T13:03:49+00:00","dateModified":"2023-11-27T13:03:51+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=89194"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=89194#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=89194","url":"https:\/\/ifintechworld.com\/?p=89194","name":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-11-27T13:03:49+00:00","dateModified":"2023-11-27T13:03:51+00:00","description":"\u00a9 Reuters. Sanofi (NASDAQ:) and Regeneron (NASDAQ:) Pharmaceuticals are preparing for an accelerated filing with the U.S. Food and Drug Administration","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=89194#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=89194"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=89194#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi and Regeneron set to file for FDA approval of Dupixent for COPD"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/89194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=89194"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/89194\/revisions"}],"predecessor-version":[{"id":89196,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/89194\/revisions\/89196"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/89195"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=89194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=89194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=89194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}